Joann Chang, MD
Ophthalmology · Lancaster, MANPI 1730359100
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,038 of the $39,707 with a category attached, or 78.2%. AbbVie accounts for 87.7% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $12,300 and has fallen 93.6% since, to $787 in 2025. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $298.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$35K
- Alcon$1K
- Rxsight Inc$652
- Oyster Point Pharma, Inc.$494
- Sun Pharmaceutical Industries Inc.$476
- Tarsus Pharmaceuticals, Inc.$295
- plus $2K from 15 others
What the payments were for
- Speaking & faculty fees$31,03878%
- Travel & lodging$2,3016%
- Food & beverage$6,35116%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 62 | $34,822 |
| Alcon | 23 | $1,107 |
| Rxsight Inc | 7 | $652 |
| Oyster Point Pharma, Inc. | 6 | $494 |
| Sun Pharmaceutical Industries Inc. | 7 | $476 |
| Tarsus Pharmaceuticals, Inc. | 2 | $295 |
| Bausch & Lomb Americas Inc. | 4 | $270 |
| Aerie Pharmaceuticals, Inc. | 2 | $211 |
| Shire North American Group Inc | 2 | $203 |
| Novartis | 2 | $143 |
| Eyevance Pharmaceuticals LLC | 1 | $125 |
| Mallinckrodt Enterprises LLC | 1 | $121 |
| Dompe US, Inc. | 1 | $120 |
| Apellis Pharmaceuticals, Inc. | 1 | $118 |
| Johnson & Johnson Vision Care, Inc. | 1 | $118 |
| Genentech USA, Inc. | 1 | $117 |
| Mallinckrodt Hospital Products Inc. | 1 | $104 |
| Ocular Therapeutix, Inc. | 4 | $66 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $64 |
| Carl Zeiss Meditec USA, Inc. | 1 | $60 |
| Rayner Intraocular Lenses Limited | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESTASIS$17,207
- RESTASIS MULTIDOSE$10,920
- VUITY$5,738
- Clareon$405
- RXSIGHT CONTACT LENS$375
- RXSIGHT INJECTOR CARTRIDGE$375
- RXSIGHT INJECTOR HANDPIECE$375
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$375
- XDEMVY$295
- LIGHT ADJUSTABLE LENS (LAL)$274
- XIIDRA$238
- CEQUA$236
- ACTHAR$225
- TYRVAYA$209
- TORIC$156
- Flarex$125
- Rocklatan$125
- Rhopressa$125
- BROMSITE$121
- XELPROS$121
How this compares
$39,708 in reported general payments places this provider in the 90th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $336,081 |
| RestasisCyclosporine | 199 | $258,493 |
| XiidraLifitegrast | 52 | $94,046 |
| MieboPerfluorohexyloctane/Pf | 83 | $61,905 |
| TyrvayaVarenicline Tartrate | 69 | $49,670 |
| Cyclosporine | 55 | $32,940 |
| Bromfenac Sodium | 144 | $23,224 |
| Prednisolone Acetate | 679 | $21,340 |
| IlevroNepafenac | 43 | $15,999 |
| LotemaxLoteprednol Etabonate | 41 | $14,707 |
| BromsiteBromfenac Sodium | 39 | $10,997 |
| CequaCyclosporine | 12 | $9,025 |
| Loteprednol Etabonate | 37 | $6,947 |
| Ketorolac Tromethamine | 275 | $4,777 |
| Fluorometholone | 44 | $3,310 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $120 | $336,08112 claims |
| AbbVieRestasis | $34,822 | $258,493199 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $270 | $155,951135 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $494 | $49,67069 claims |
| Sun Pharmaceutical Industries Inc.Bromsite, Cequa | $476 | $20,02251 claims |
| NovartisIlevro | $143 | $15,99943 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 653 ophthalmology providers in Massachusetts.
Other ophthalmology in Lancaster
- Rishi SinghBoston$1.7M
- Peter ChangWaltham$992K
- Stephen AnesiWaltham$922K
- David LallySpringfield$328K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Mark LatinaReading$279K
- Dean EliottBoston$250K
- Jeremy KievalLexington$232K
- Mina FarahaniBoston$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.